Web resources for drug toxicity

被引:18
作者
Wolfgang, GHI [1 ]
Johnson, DE [1 ]
机构
[1] ddplatform LLC, Oakland, CA 94608 USA
关键词
drug development; in silico toxicology; regulatory toxicology;
D O I
10.1016/S0300-483X(02)00022-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Information on drug toxicity is used primarily by three segments of the health care industry: the consumer or patient, healthcare practitioners, and research and development (R&D) scientists in the pharmaceutical industry. The major focus of both consumers and health care practitioners is the provision of suitable information for the safe use of drugs for both individuals and specific patient populations. Therefore, accurate information on potential side effects and drug-drug and food-drug interactions is critical. For pharmaceutical scientists, the use of toxicity information is more complex and has become an essential part of the R&D process. The high rate of failures in drug development has precipitated the utilization of all available resources to gather relevant information that may improve the process of drug development. The web is a growing source of information and services for the pharmaceutical industry. Web-based resources for non-clinical drug development include tools for virtual discovery such as silico ADME/Toxicity programs, access to information regarding in vitro and in vivo testing, new data management options, and the latest regulatory guidelines and industry news. These resources are reviewed from the perspective of a toxicologist. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 18 条
[1]  
*AND CONS, 1997, REINV DRUG DISC ISS
[2]   Combinatorial library design for diversity, cost efficiency, and drug-like character [J].
Brown, RD ;
Hassan, M ;
Waldman, M .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2000, 18 (4-5) :427-+
[3]   Computational methods for the prediction of 'drug-likeness' [J].
Clark, DE ;
Pickett, SD .
DRUG DISCOVERY TODAY, 2000, 5 (02) :49-58
[4]   SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].
DIMASI, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14
[5]   The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology [J].
Haverkamp, W ;
Breithardt, G ;
Camm, AJ ;
Janse, MJ ;
Rosen, MR ;
Antzelevitch, C ;
Escande, D ;
Franz, M ;
Malik, M ;
Moss, A ;
Shah, R .
CARDIOVASCULAR RESEARCH, 2000, 47 (02) :219-233
[6]  
Johnson Dale E., 2001, Current Topics in Medicinal Chemistry, V1, P233, DOI 10.2174/1568026013395128
[7]   Predicting human safety: screening and computational approaches [J].
Johnson, DE ;
Wolfgang, GHI .
DRUG DISCOVERY TODAY, 2000, 5 (10) :445-454
[8]   Screening for human ADME/Tox drug properties in drug discovery [J].
Li, AP .
DRUG DISCOVERY TODAY, 2001, 6 (07) :357-366
[9]  
Madden S, 2001, Curr Opin Drug Discov Devel, V4, P66
[10]  
Matthews EJ, 2000, J MOL GRAPH MODEL, V18, P605